Literature DB >> 2535793

Regional chemotherapy in an experimental model of Wilms' tumor in rats.

P M Andrews1, C L Johnson.   

Abstract

A s.c. experimental model of Wilms' tumor in rats was used to compare the effects of intratumoral treatment with vincristine plus actinomycin D to i.v. treatment with these chemotherapeutic drugs. The Wilms' tumor model is a fast-growing solid tumor that has been shown to be resistant to traditional clinical treatment procedures used for Wilms' tumor in man. Injection of the chemotherapeutic drugs directly into the tumor mass was found to be more effective than i.v. therapy in causing long-term remission of the tumor. Intratumoral therapy was also less toxic to the animals than i.v. therapy when measured by post-treatment survival rates and weight loss during the 1st week following treatment. However, intratumoral treatment caused an initial fibrosis of the tumor tissue, which resulted in a slower rate of absorption of the resultant fibrotic tumor mass than was seen in tumors treated i.v. Also, intratumoral injection resulted in necrosis of the overlying skin, which healed as the fibrotic tumor tissue was absorbed. Intratumoral treatment of a cervical tumor was found to cause the remission of a second major tumor mass located at some distance from the initial injection (i.e., in the lumbar region). No significant benefits were noted when dimethylsulfoxide (DMSO) was used in place of aqueous mannitol as a vehicle to deliver the chemotherapeutic agents. There was a significant correlation between the drug dose-to-tumor-size ratio (D/T ratio) and the effectiveness of the chemotherapy. When this ratio was high enough, a single treatment with a combination of vincristine and actinomycin D usually resulted in total remission of the experimental Wilms' tumor in response to either intratumoral or i.v. therapy.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2535793     DOI: 10.1007/bf00258454

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  JET INJECTION OF DRUGS INTO MALIGNANT NEOPLASMS.

Authors:  R L LAWTON
Journal:  Cancer Chemother Rep       Date:  1964-04

2.  EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.

Authors:  H E SKIPPER; F M SCHABEL; W S WILCOX
Journal:  Cancer Chemother Rep       Date:  1964-02

3.  Beneficial effects of adriamycin on Wistar-Furth Wilms' tumor.

Authors:  G P Murphy; P D Williams
Journal:  Urology       Date:  1975-06       Impact factor: 2.649

4.  A murine Wilms' tumor as a model for chemotherapy and radiotherapy.

Authors:  P Tomashefsky; Y L Homsy; J K Lattimer; M Tannenbaum
Journal:  J Natl Cancer Inst       Date:  1976-01       Impact factor: 13.506

5.  Kinetics of 57Co-bleomycin in mice after intravenous, subcutaneous and intratumoral injection.

Authors:  J Bier; P Benders; M Wenzel; K Bitter
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

Review 6.  Topical antimetabolites.

Authors:  H S Zackheim; E M Farber
Journal:  Annu Rev Med       Date:  1970       Impact factor: 13.739

Review 7.  Intravesical chemotherapy of superficial bladder cancer.

Authors:  B L Lum
Journal:  Recent Results Cancer Res       Date:  1983

Review 8.  Novel modes of chemotherapy administration.

Authors:  D J Stewart
Journal:  Prog Exp Tumor Res       Date:  1984

9.  DMSO-cytostatic complexes: selective cancer chemotherapy.

Authors:  K Setälä
Journal:  Ann N Y Acad Sci       Date:  1983       Impact factor: 5.691

10.  Palliation of cancer in human patients by maintenance therapy with NN'N"-triethylene thiophosphoramide and N-(3-oxapentamethylene)-N'N"-diethylene phosphoramide.

Authors:  J C BATEMAN
Journal:  Ann N Y Acad Sci       Date:  1958-04-24       Impact factor: 5.691

View more
  1 in total

1.  Intratumoural administration of cisplatin in slow-release devices. I. Tumour response and toxicity.

Authors:  M J Deurloo; S Bohlken; W Kop; C F Lerk; W Hennink; H Bartelink; A C Begg
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.